Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and ß1 Integrin in Patients with Hodgkin's Lymphoma.

Kouhpayeh, Shirin; Andalib, Alireza; Gharagozloo, Marjan; Sanei, Mohammad Hossein; Esmaeil, Nafiseh; Maracy, Mohammad Reza

Kouhpayeh, Shirin; Andalib, Alireza; Gharagozloo, Marjan; Sanei, Mohammad Hossein; Esmaeil, Nafiseh; Maracy, Mohammad Reza.

Afiliação

Kouhpayeh S; Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Andalib A; Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Gharagozloo M; Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Sanei MH; Department of Pathology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Esmaeil N; Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Maracy MR; Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.

Adv Biomed Res ; 6: 108, 2017.

Article em En | MEDLINE | ID: mdl-28904936

Palavras-chave

Hodgkin's lymphoma; metastasis; soluble urokinase plasminogen activator receptor; urokinase plasminogen activator receptor; ß1 integrin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Adv Biomed Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google